Publication

Clozapine-induced hepatitis confirmed by rechallenge

Kanani, Muhammad-Kazim
; 
Nandhra, Harpal
Abstract
Clozapine is an atypical antipsychotic that holds a unique role in the management of treatment-resistant schizophrenia. Well known side-effects include agranulocytosis and myocarditis but associated hepatic disorders are less familiar and listed under ‘rare or very rare’ by the British National Formulary.1 However, a transient elevation of transaminases has been estimated to affect up to 50% of patients treated with clozapine.2 This article describes a patient with minimally elevated LFTs who subsequently developed symptomatic hepatitis following the initiation of clozapine therapy.
MIDER Authors
Kanani, Muhammad-Kazim
Nandhra, Harpal
Citations
Altmetric:
Date
2019-08-13
Type
Article
Subject
Pharmacology, Gastroenterology, Mental health
Collections
CWPT Medicines Management
Patient Information Leaflets
Show all metadata
Citation
Kanani MK, Nandhra H. Clozapine-induced hepatitis confirmed by rechallenge. Progress in Neurology and Psychiatry 2019; 23(3): 18–20.
Journal / Source Title
Progress in Neurology and Psychiatry
DOI
10.1002/pnp.542
URI
http://hdl.handle.net/20.500.14200/7579
PMID
Publisher
Wiley
Publisher’s URL
https://onlinelibrary.wiley.com/doi/10.1002/pnp.542
Publisher’s statement
Note / Copyright